April 7 (Reuters) – Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to $5 billion, as the U.S. drugmaker looks to boost its pipeline with a lucrative class of experimental cancer drugs referred to as “guided missiles”.<\/p>\n
\n This marks the latest in Gilead’s acquisition spree. The company has been expanding beyond its key areas for growth amid looming patent expiries and declining sales of its COVID-19 treatment.<\/p>\n
\n In February, the drugmaker bought partner Arcellx for up to $7.8 billion, its biggest deal since 2020, to strengthen its lineup of cancer treatments. Last month, it agreed to acquire privately held biotech firm Ouro Medicines in a deal worth more than $2 billion ?to expand its pipeline of immune disorder drugs.<\/p>\n
\n With the latest deal, Gilead will get access to Tubulis’ drugs, which belong to the class called antibody-drug conjugates (ADC), popularly known as “guided missiles”, that deliver chemotherapy directly to cancer cells while minimizing harm to healthy tissue. <\/p>\n
\n Tubulis’ lead asset, TUB-040, which binds to NaPi2b, a protein found in certain cancer cells, is currently in early-stage development for a type of ovarian cancer and non-small cell lung cancer.<\/p>\n
\n Another experimental drug, TUB-030, is being studied across various solid tumor types.<\/p>\n
\n “The agreement to acquire Tubulis is a significant milestone in Gilead’s progress in oncology,” said Gilead CEO Daniel O’Day.<\/p>\n
\n Under the terms of the deal, Gilead will acquire all of the outstanding equity of Tubulis for $3.15 billion in upfront cash, payable at closing, and up to $1.85 billion in milestone payments.<\/p>\n
\n The companies have previously entered into licensing agreements to develop ADCs. Tubulis also has a partnership with Bristol-Myers Squibb <\/p>\n
\n Following the close of the transaction, expected in the second quarter of 2026, Tubulis will operate as an ADC research organization within Gilead.<\/p>\n
\n (Reporting by Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)<\/p>\n","protected":false},"excerpt":{"rendered":"April 7 (Reuters) – Gilead said on Tuesday it would acquire private Germany-based Tubulis GmbH for up to…\n","protected":false},"author":2,"featured_media":2809,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[5,548],"class_list":{"0":"post-2808","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-germany","8":"tag-germany","9":"tag-markets"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/2808","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/comments?post=2808"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/posts\/2808\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media\/2809"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/media?parent=2808"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/categories?post=2808"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/germany\/wp-json\/wp\/v2\/tags?post=2808"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}